Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Industries and raises the price target from $22 to $25.
October 23, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Balaji Prasad has maintained an Overweight rating on Teva Pharmaceutical Industries and increased the price target from $22 to $25, indicating a positive outlook on the stock.
The increase in price target from $22 to $25 by Barclays suggests a positive outlook on Teva's stock, likely leading to a short-term price increase. The Overweight rating indicates confidence in the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100